Diabetes. 2016 Jan;65(1):269-75. doi: 10.2337/db15-0893. Epub 2015 Oct 15. % a* ~4 I0 ~6 U4 ?+ BThe Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial. l0 O, G0 p* ^/ ~; qThazhath SS1, Marathe CS1, Wu T1, Chang J1, Khoo J1, Kuo P2, Checklin HL1, Bound MJ1, Rigda RS1, Crouch B3, Jones KL1, Horowitz M1, Rayner CK4 8 z( R) d8 [! G* ^7 m& u8 ?7 _! ~
Link: http://diabetes.diabetesjournals.org/content/65/1/269.long + h. u$ y6 J. n [* I. O9 r, U$ E
W; n2 B& t# a0 B6 K' r% V
Thanks so much!作者: farui 时间: 2016-1-7 22:34
The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial * k* [$ a. P. z7 N[attach]74680[/attach]